Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Duchenne Muscular Dystrophy

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Nephrology

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

PTSD

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Skin Cancer

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

Emerging Leaders

Interactive Tools

PBM Leaders

Subscribe

Videos

Medicaid Changes Could Burden Hospitals and Strain Community Health Plans

Employers and Medicare trustees could come together and change the healthcare industry, leading to healthcare reform, according to Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company.

Healthcare Reform: Employers and Narrow Networks Could Drive Cost-Effective Patient Outcomes

Articles

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

FDA Approves Amvuttra for ATTR-CM in Extended Label 

It was found that Microsoft 365 was the most frequently compromised platform, responsible for 43.3% of breaches.

Email Remains a Leading Security Risk in Healthcare

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

Dermatology Conference Coverage

AMCP Annual

Emerging Leaders in Healthcare

K-Cast: Optimizing Narcolepsy Care

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Continuing Medical Education

Benjamin P. Levy, MD; Ignacio I. Wistuba, MD; Lynette M. Sholl, MD; Kristen A. Marrone, MD;

Tissue Stewardship and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Julie R. Brahmer, MD, MSc, FASCO; Bruna Pellini, MD; Jaime Laurel Schneider, MD, PhD; Mark A. Socinski, MD

Community Practice Connection™: 21st Annual Winter Lung Cancer Conference®

Melissa Johnson, MD; Edward Garon, MD, MS; Solange Peters, MD, PhD; Ignacio I. Wistuba, MD

Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights Into Predicting Pathologic Responses to Immunotherapies

Stephen V. Liu, MD; Benjamin P. Levy, MD, FASCO; Laura Macke, MS, BSN, FNP-C, AOCNP; Michelle M. Turner, MSN, CRNP

Navigating Current State-of-the Art NSCLC Patient Care From the Front Lines: Essentials for Oncology Nurses Today and Tomorrow

BURST CME™: How Are Emerging Biomarkers and Testing Methodologies Shaping Personalized Medicine in NSCLC?

Edward S. Kim, MD, MBA; Leah M. Backhus MD, MPH, FACS; Lyudmila A. Bazhenova, MD

Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?

Melissa Johnson, MD; Dara Aisner, MD, PhD; David R. Gandara, MD; Balazs Halmos, MD, MS

Top 10 Oncogenic Drivers in NSCLC for 2024: Where Are We and Where Are We Going?

Karen M. Winkfield, MD, PhD; Narjust Florez, MD, FASCO; Gilberto de Lima Lopes Junior, MD, MBA, FASCO; Coral Olazagasti, MD; Vonetta M. Williams, MD, PhD

 Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

Ticiana Leal, MD; Jennifer W. Carlisle, MD; Nisha Mohindra, MD; Martin Wermke, MD

DLL3 as a Therapeutic Target in SCLC and Beyond: Rationale, Recent Data and Potential for Transformations in Care with T-Cell Engagers

Anne Chiang, MD, PhD; Megan E. Daly, MD; Carl M. Gay, MD, PhD; Jacob Sands, MD

Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?

26th Annual International Lung Cancer Congress®

Advances In™: Moving Care Forward in SCLC with DLL3 Targeting Bispecific T-Cell Engagers

Jeneth Aquino, DNP, FNP-BC; Beth Sandy, MSN, CRNP, FAPO; Allison M. Walker, ACNP, MSN, MSW, BS

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

Jacob Sands, MD; Myung-Ju Ahn, MD; Aaron Lisberg, MD

What’s Next for HER2- and TROP2-Directed ADCs in Lung Cancer: How Emerging Trial Data will Impact our Clinics Today, and Tomorrow….

Anne Chiang, MD, PhD; Jonathan Wesley Riess, MD, MS; Misty D. Shields, MD, PhD

Do We Have Sea Change in Small Cell Lung Cancer? What Recent Clinical Trial Data Tell Us About Treatment Decision-Making in Real-World Settings, What’s Next for Emerging Novel Strategies

David R. Gandara, MD; Roy S. Herbst, MD, PhD; Pasi Jänne, MD, PhD; Heather A. Wakelee, MD, FASCO

Community Practice Connections™: 25th Annual International Lung Cancer Congress

Beth Sandy, MSN, CRNP, FAPO; Laura Wood, RN, MSN, OCN; Michael Lai, ARNP; Tiffany Richards, PhD, ANP-BC, AOCNP®; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Megan Wanca, APRN, DNP, FNP-C

Community Practice Connections™: 8th Annual School of Nursing Oncology™

Charu Aggarwal, MD, MPH, FASCO; Christine Bestvina, MD; Hatim Husain, MD; Karen L. Reckamp, MD, MS

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

Percy Lee, MD, FASTRO; David Harpole Jr, MD; Julia Rotow, MD

(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

Megan E. Daly, MD; Nagla F. Abdel Karim, MD, PhD; Chul Kim, MD

(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

20th Annual New York Lung Cancers Symposium®

Jacob Sands, MD; Beth Sandy, MSN, CRNP, FAPO; Stephanie McDonald, FNP-BC, AOCNP

Virtual Tumor Board for the Onco-Nurse: Improving Outcomes in SCLC Treatment and AE Management

Mark G. Kris, MD; Justin Gainor, MD; Isabel Preeshagul, DO, MBS; Helena A. Yu, MD

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Anne Chiang, MD, PhD; Erminia Massarelli, MD, PhD, MS; Zofia Piotrowska, MD, MHS 

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Annual Hawaii Cancer Conference

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

 Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

Balazs Halmos, MD, MS; Mark G. Kris, MD; Jamie E. Chaft, MD; Zofia Piotrowska, MD, MHS

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

Benjamin P. Levy, MD; John O. Mascarenhas, MD; Tiffany A. Traina, MD, FASCO; Cathy Eng, MD, FACP, FASCO; John P. Leonard, MD

 42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

David R. Gandara, MD; Roy S. Herbst, MD, PhD; Heather A. Wakelee, MD, FASCO

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

Zofia Piotrowska, MD, MHS; Bruna Pellini, MD; Alice Shaw, MD, PhD

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Upcoming CME Events & Activities

EVENTS

ACTIVITIES